TPST - Tempest Therapeutics, Inc.

0.5006
-0.005   -1.039%

Share volume: 759,248
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.51
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 0%
Dept financing 43%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-18.48%
1 Month
-36.50%
3 Months
-47.27%
6 Months
-62.92%
1 Year
-87.06%
2 Year
-81.11%
Key data
Stock price
$0.50
P/E Ratio 
0.00
DAY RANGE
$0.50 - $0.56
EPS 
-$1.09
52 WEEK RANGE
$0.41 - $3.94
52 WEEK CHANGE
-$86.54
MARKET CAP 
36.419 M
YIELD 
N/A
SHARES OUTSTANDING 
25.208 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
3.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,342,660
AVERAGE 30 VOLUME 
$725,387
Company detail
CEO: Stephen R. Brady
Region: US
Website: tempesttx.com
Employees: 20
IPO year: 2012
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.

Recent news
loading